Zentalis Intangible Assets from 2010 to 2026
| ZNTL Stock | USD 2.39 0.05 2.14% |
Intangible Assets | First Reported 2010-12-31 | Previous Quarter 7.9 M | Current Value 7 M | Quarterly Volatility 465.2 K |
Check Zentalis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zentalis Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 167.3 K, Net Interest Income of 469.1 K or Interest Income of 469.1 K, as well as many indicators such as Price To Sales Ratio of 3.49, Dividend Yield of 0.0 or PTB Ratio of 0.7. Zentalis financial statements analysis is a perfect complement when working with Zentalis Pharmaceuticals Valuation or Volatility modules.
Zentalis | Intangible Assets | Build AI portfolio with Zentalis Stock |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Zentalis Pharmaceuticals Correlation against competitors. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. Anticipated expansion of Zentalis directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Zentalis Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Zentalis Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.